What is “letrozole 2.5 mg” used for?
Letrozole 2.5 mg is the usual strength of letrozole, an aromatase inhibitor used mainly for hormone-receptor–positive breast cancer in postmenopausal women. It works by lowering estrogen levels, which can slow the growth of estrogen-dependent tumors.
How do patients typically take letrozole 2.5 mg?
The standard adult dose is usually 2.5 mg by mouth once daily for the approved indications. Exact instructions can vary by the treatment plan and whether the drug is being used as adjuvant therapy, for extended adjuvant therapy, or for metastatic disease, so patients should follow the prescription directions.
What side effects are most common with letrozole 2.5 mg?
Common side effects reported with letrozole include hot flashes, joint and muscle aches, fatigue, and increased cholesterol. It can also affect bone health, so clinicians often monitor for osteoporosis or fracture risk.
Does letrozole 2.5 mg affect bone density?
Yes. Because it lowers estrogen, letrozole can reduce bone mineral density over time. Patients may need bone-density monitoring (and sometimes medications to protect bone) depending on age, baseline bone health, and treatment duration.
What should someone tell their clinician before starting letrozole?
Clinicians typically want to know about:
- Past or current osteoporosis or fractures
- Other medications and supplements
- Liver disease history (since drug handling involves the liver)
- Any prior hormone-therapy treatments
Are there alternatives to letrozole 2.5 mg?
For hormone-receptor–positive breast cancer, other endocrine therapies may include different aromatase inhibitors or selective estrogen receptor modulators/downstream estrogen pathway drugs, depending on menopausal status and the specific stage of disease. The best choice depends on prior treatments and risk factors for bone loss.
Where can I check letrozole patents or generic availability?
If you’re researching patent status, exclusivity, or generic/biosimilar competition, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/